The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.

COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial (413720)

ARTG ID 413720

ARTG Name

COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial

Product name

COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial

ARTG Date

21 December 2023

Registration Type

Medicine

Therapeutic good type

Medicine

Ingredients

famtozinameran

tozinameran

Licence category

REP

Licence status

A

Summary

Product Information

Consumer Medicine Information

COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial (2023-24)

2023-24

Annual charge exemption

Exempt from annual charge in 2023-24 due to Pfizer Australia Pty Ltd declaring $0 turnover in that period.
COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial, Pfizer Australia Pty Ltd, CON-1305

9 December 2024

Section 14 consent

Consent to while noncompliant with standards. The consent is effective from 9 December 2024 until 1 October 2026.